Compared with the control arm, treatment with carboplatin and paclitaxel plus bevacizumab (15 mg/kg) resulted in a higher response rate (31.5% v 18.8%), longer median time to progression (7.4 v 4.2 ...

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

On Monday, the agency approved the PD-1-directed immune checkpoint inhibitor pembrolizumab (Keytruda), in combination with carboplatin and paclitaxel, for patients with either mismatch repair (MMR ...

A panelist discusses how the FDA approval and NCCN endorsement of retifanlimab plus carboplatin/paclitaxel represents a ...

Panelists discuss how current NCCN guidelines for metastatic anal cancer recommend carboplatin-paclitaxel as preferred first-line therapy, with the recent addition of carboplatin-paclitaxel plus ...

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

DelveInsight’s Advanced Ovarian Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Ovarian Cancer treatment.

Panelists discuss how implementing combination immunotherapy in clinical practice faces institutional barriers, including ...

Patients with advanced lung cancer may have a safer chemotherapy treatment option. TAXOL (paclitaxel) plus Paraplatin (carboplatin), administered in a novel weekly regimen, offers a safe and ...

Background: Carboplatin combined with paclitaxel are considered treatment of choice as initial chemotherapy for AOC. We compared this combination with a regimen combining cisplatin plus paclitaxel and ...

Rates of HER2 expression are examined and trastuzumab is tested in combination with paclitaxel and carboplatin in patients with resistant advanced ovarian cancer. X. No Results.